Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax Glucophage XR Generic Exclusivity Extended; New Twist On “Late-List”

Executive Summary

Ivax will gain at least an additional 30 days of generic marketing exclusivity for Bristol-Myers Squibb's Glucophage XR after a federal judge issued a temporary restraining order blocking FDA from approving other metformin extended-release ANDAs
Advertisement

Related Content

Glucophage XR generics
Glucophage XR generics
Bristol/Teva “Authorized” Generic Agreement Approved By FTC
Ribavirin ANDAs Clear FDA; Schering Goes Generic Too
Paxil Generics On Hold After Court Rejects FDA “Shared Exclusivity” Policy
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Bristol Renounces Late-Listed Patents Under FTC Settlement
Advertisement
UsernamePublicRestriction

Register

PS044119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel